Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com

# Australian Microcap Investment Conference presentation

**11 May 2026 – Melbourne Australia**: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to provide the presentation to be delivered at the 15th Annual Australian Microcap Investment Conference, being held in Sydney, Australia on 11 May 2026.

The presentation will be delivered by Chief Operating Officer, Mr John Clark, and forms part of Neurizon's ongoing investor engagement activities aimed at increasing awareness of the Company's clinical development programs, strategic progress and upcoming milestones among Australian and international investors.

The Australian Microcap Investment Conference is one of Australia's leading investment conferences focused on the microcap sector, bringing together members of the investment community to hear directly from ASX-listed companies with market capitalisations under A$300 million. Following its long-standing success in Melbourne, the conference has expanded to Sydney in 2026.

The presentation provides an overview of Neurizon's development activities for NUZ-001, including recent recruitment progress in the HEALEY ALS Platform Trial, operational execution, and upcoming clinical and corporate milestones.

The presentation slides are attached to this announcement.

-ENDS-

This announcement has been authorised for release by Sergio Duchini, Interim Executive Chairman on behalf of the Board of Neurizon Therapeutics Limited.

**For any questions, comments, or further information regarding Neurizon, please email enquiries@neurizon.com, or contact:**

**Marketing & Corporate Affairs**
Lidija Damjanovic
Marketing & Corporate Affairs
Email: lidija@neurizon.com
Phone: +61 (0) 425 700 504

**Investor Relations**
Henry Jordan
Six Degrees Investor Relations
Email: henry.jordan@sdir.com.au
Phone: +61 (0) 431 271 538

## About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

## Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon.
This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit
https://investorhub.neurizon.com

Neurizon

# Neurizon Therapeutics

## A promising new horizon in neurodegenerative diseases

**John Clark, Chief Operating Officer**

Australian Microcap Investment Conference

May 2026, Sydney

ABN 35 094 006 023

# Disclaimer

This disclaimer applies to this presentation and the information contained in it (This presentation has been prepared by Neurizon Therapeutics Limited (ASX: NUZ) (the "Company")). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company.
The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

## Future Matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

## US Disclosure

This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 ("Securities Act"). The Company's shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.


# Our Vision

To lead the development of neurodegenerative treatments towards a promising new horizon for patients.

Neurizon

# Our Promise

Accelerating Patient Access to Innovative ALS Treatment

Driving Clinical Progress

Unlocking the potential of Neurizon to address high unmet need in neurodegenerative diseases

Delivering commercial readiness and stakeholder value

# Neurizon: From Scientific Origin to Clinical Momentum

## A unique opportunity in neurodegenerative diseases

Well characterised drug | Disease-modifying potential | Strong foundation | Late-stage clinical execution

1

**DISCOVERY & FOUNDATION**

2005 - 2013



**Monepantel – a proven veterinary product with extensive safety and pharmacology data**

2

**TRANSLATION TO HUMAN DISEASE**

2013 - 2021

**From veterinary use to potential in neurodegenerative diseases**

3

**NEURIZON FORMATION & STRATEGY**

2022 - 2023

**Building a focused clinical-stage company with the clear focus on neurodegenerative diseases**

4

**CLINICAL VALIDATION & HEALEY SELECTION**

2024 - 2025

**NUZ-001 Phase 1 results show early signals of efficacy in a small study with people living with ALS/MND and drive inclusion into HEALEY trial**

5

**CLINICAL EXECUTION**

2026 - 2027

**Active execution of Registrational Phase 2/3 HEALEY ALS Platform Trial**

NUZ-001 is a well-characterised molecule, with novel neurodegenerative biology, and is now advancing through a registrational Phase 2/3 clinical program

# NUZ-001: Potential application to range of neurodegenerative diseases

ALS is a current priority, but NUZ-001 has potential application to a range of neurodegenerative diseases.

**NUZ-001** is a **mechanism-driven**, disease-agnostic approach to treating neurodegeneration by **rebalancing proteostasis and addressing core cellular dysfunction**.

New preclinical data show NUZ-001 increases activity of **multiple protein clearance pathways** in neuronal models: **autophagy and proteasomal systems.**

**TDP-43**
ALS/AD/PD/FTD/CTE



**Amyloid beta**
AD/PD



**Tau**
AD/PD/FTD/CTE/PSP



**alpha Synuclein**
AD/PD



**mHTT**
HD



AD = Alzheimer's Disease; ALS = Amyotrophic Lateral Sclerosis; CTE = Chronic Traumatic Encephalopathy; FTD = Frontotemporal Dementia; HD = Huntington Disease; PD = Parkinson's Disease; PSP = Progressive Supranuclear Palsy

# HEALEY Trial: Opportunity for accelerated approval

Initial focus is ALS, a rare disease with high unmet need and the possibility of accelerated approval on Phase 2/3 data. Potential for broader application being developed through pre-clinical program.




## Strongly Positioned with Regulatory and Commercialisation Requirements for Realisation

Access to animal safety data and manufacturing data critical to support future trials and potential regulatory approvals

Access to manufacturing at scale critical to future commercialisation

Derisked regulatory approval process



# Phase 1 ALS MEND Study and Open Label Extension

## Early Signals of Efficacy

Neurizon

# Phase 1 Open Label Extension

## Preliminary Efficacy ALSFRS-R and SVC

Treatment with NUZ-001 across combined Phase 1 and OLE studies slowed the progression of ALS in all patients by 31% for ALSFRS-R and 43% for SVC percent predicted (PP) when compared to matched controls from the PRO-ACT historical database[1]

**Motor Function – ALSFRS-R**




**Respiration – SVC PP[2]**




1. Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, Walker J, Katsovskiy I, Schoenfeld D, Cudkowicz M, Leitner M. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014 Nov 4;83(19):1719-25. doi: 10.1212/WNL.0000000000000951.Epub 2014 Oct 8. PMID: 25298304; PMCID: PMC4239834
2. Forced vital capacity (FVC) was used when SVC was not collected
3. Matched on time since onset, baseline ALSFRS-R, pre-baseline slope, and disease onset location

# Phase 1 Open Label Extension
## Survival Probability Analysis

Compared to matched controls from the PRO-ACT database, treatment with NUZ-001 results in significantly longer survival of patients with ALS ($X^2$=10.95, p=0.00094) .

| Analysis Method | | Log-Rank Test | | Cox Proportional Hazards Model | | |
|---|---|---|---|---|---|---|
| Dataset | Death Time Imputation | $\chi^2$ | p-value | Hazard Ratio | 95% CI | p-value |
| Assumed Survival | Leave out | 10.95 | 0.00094 | 0.298 | (0.135, 0.659) | 0.0028 |
| | Last Visit | 11.98 | 0.00054 | 0.287 | (0.131, 0.632) | 0.0019 |
| Confirmed Survival | Leave out | 16.67 | 0.00004 | 0.266 | (0.126, 0.561) | 0.0005 |
| | Last Visit | 18.43 | 0.00002 | 0.254 | (0.121, 0.534) | 0.0003 |




Hazard ratio of 0.298 (95% CI: (0.135, 0.659), p = 0.0028) suggests that treatment with NUZ-001 reduces the risk of death by 70.2%

# Phase 1 Open Label Extension
## Safety and Tolerability Summary

Study drug was shown to be safe and generally well tolerated during long-term administration in the OLE, with no dose-limiting toxicities and no treatment-related deaths.

| | Total (n) | Related to Treatment (n) |
|---|---|---|
| Adverse Events | 25 | 3 |
| Serious Adverse Events | 5 | 0 |

- No participants withdrew from study
- No serious adverse events related to study drug (Raised liver enzyme, Increased hair growth, Dry mouth at night)
- No unexpected safety findings observed in the OLE compared with Phase 1 MEND
- 3 patients still receiving treatment under the TGA's Special Access Scheme

# Registrational Phase 2/3
# HEALEY ALS Platform Trial

Neurizon

# HEALEY ALS Platform Trial Regimen ‘I’ for NUZ-001

**36-week Double Blind Placebo Controlled Period**

**36-week Active Treatment Extension Period**

**Inclusion/Exclusion Criteria**

**NUZ-001 10 mg/kg**

3:1 Randomisation
n=160 participants

**Placebo**

**NUZ-001 10 mg/kg**


**Primary Endpoint**

- Change from baseline through Week 36 in disease severity, measured by the ALSFRS-R total score and survival

**Secondary Endpoints**

- Change from baseline through Week 36 in secondary efficacy measures (e.g., respiratory function via slow vital capacity (SVC))
- Survival through Week 36 (death or equivalent endpoint)

# ‘Regimen-I’ HEALEY ALS Platform Trial Expected Key Milestones




## Anticipated Trial Execution Updates

| | |
|---|---|
| **Site Activation** | Confirmation of additional clinical sites opened and recruitment underway |
| **Enrolment Milestones Achieved** | Progress updates on patient recruitment (e.g., 50% enrolled, enrolment complete) |
| **Completion Milestones** | Last Patient In (LPI) and Last Patient Last Visit (LPLV), with timing guidance for topline data release |

# Strong Recruitment Momentum

59

Activated Sites

123

Master Screening

62

Regimen Assignment

48

Dosed Participants

Numbers referred to above are as of 5 May 2026.

# Investment Potential

Neurizon

# HEALEY: Funding secured

## Strong shareholder support has secured adequate funding for HEALEY ALS Platform trial[1]

Neurizon's funding strategy has been developed with a focus on protecting shareholders' interests through flexible funding instruments and minimising dilution. This includes the ability to finance the company's R&D rebate receivables and the ability to displace the convertible note facility, if appropriate to do so.

### Placement & Entitlement Offer

- Raised ~A$7.1 million under the Placement, through issue of New Shares at A$0.08 per New Share for the HEALEY ALS Platform Trial
- 2-for-5 Entitlement Offer at A$0.08 per New Share, which raised a total of A$8.5 million through the entitlement offer (January 2026) and the shortfall placement (April 2026).

### Research & Development (R&D) Tax Rebate

- Neurizon's Advance and Overseas Finding (AOF) provides a cash rebate for foreign R&D spend
- Cash rebate of at least 43.5% on HEALEY spend
- AOF is binding on Australian Tax Office and AusIndustry - providing an important, non-dilutive source of funds

### Convertible Note Facility

- Convertible Note Facility for up to A$20 million with Obsidian Global GP, LLC
- Initial draw of A$5 million completed in February 2026
- Committed facility - option but no obligation to use remaining A$15 million in the facility
- Includes trading restrictions to protect shareholder and optionholder interests

[1] See ASX: NUZ - Equity Raising Presentation (23 December 2025), including details of funding strategy and identified risks.

# ALS: High Unmet Need with Significant Value Potential

## A serious, rapidly progressive disease with limited treatment options.
## Meaningful innovation in ALS can create value for people living with ALS and the market.

### THE NEED IN ALS

**~30,000+**
people living with ALS in the U.S only.[1]

**Rapid progression**
Median survival often 2–5 years from diagnosis[2]

**High unmet need**
Limited treatment options. Need remains for therapies addressing underlying disease biology.

### WHY NUZ-001 IS RELEVANT




**Addresses key ALS pathology**
Aims to inhibit TDP-43 aggregation and restore proteostasis (NUZ-001 mechanism of action).

**Clinical-stage program**
Entered Phase 2/3 HEALEY ALS Platform Trial.

**Oral administration**
Convenient, scalable formulation with the potential for broad patient access.

**Multi-Indication potential**
Exploring relevance in other neurodegenerative diseases with shared pathology.

### COMMERCIAL VALUE POTENTIAL

**ALS market has demonstrated significant strategic value**

- Multiple large-value transactions and licensing deals in recent years.
- Strong interest in differentiated therapies, particularly with oral or disease-modifying potential.

**Potential value drivers for Neurizon**

- Appeared safe and generally well-tolerated with signals of efficacy in exploratory studies
- Regulatory milestones
- Partnership and licensing optionality
- Pipeline expansion into HD and other neurodegenerative diseases

1. The ALS Association; www.als.org; accessed April 2026
2. Chio A, et al Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10(5-6);310-323

# ALS: High Unmet Need with Significant Value Potential

## Multiple large-value transactions and deals in recent years

### Key ALS Value Reference Point: Shionogi – RADICAVA US$2.5B Transaction (April 2026)[1]

**Transaction**: Shionogi acquired global rights to RADICAVA (IV edaravone) and RADICAVA ORS (oral edaravone) from Tanabe Pharma.

**Deal value**: US$2.5 billion upfront (lump sum), with potential additional royalties on future sales (subject to conditions).

**Timing**: Announced 22 December 2025 and completed in early April 2026

**Asset profile**: A commercial, revenue-generating ALS therapy franchise with both IV and oral formulations already in market.

**Strategic rationale**: Strengthened Shionogi's rare disease commercial platform (especially US), adding established programs/teams and readiness to launch additional rare disease treatments.


### Other Recent ALS Deals

**Eli Lilly** entered neurodegenerative disease collaborations with Alchemab[2] (2025; reported up to US$415M) and QurAlis[3] (2024; US$45M upfront plus potential milestones).

**Eli Lilly** and Verge Genomics[4] entered an ALS discovery collaboration in 2021. Public reports described potential transaction economics of approximately US$694M.

**Ferrer**: Prilenia and Ferrer announced a strategic collaboration and licensing agreement relating to pridopidine in 2025.[5]

1. Shionogi press release, 22 December 2025; transaction completion announced April 2026.
2. Alchemab Therapeutics press release, 6 May 2025
3. QurAlis press release, 3 June 2024
4. Fierce Biotech, 6 January 2021
5. Prilenia Therapeutics press release, 28 April 2025

# NUZ-001: Strong portfolio protection

In addition to patent protection, NUZ-001 has US Orphan Drug Designation (ODD) and European Orphan Medicinal Product Designation (OMPD) providing 7 and 10 years of market exclusivity, respectively.

**Patent Families for monepantel**




**What is protected:**

- Key analogues of monepantel
- Optimised dosing, formulation and combo strategies
- Monepantel use in neurodegenerative and mTOR-related diseases

**Protected Jurisdictions:**

1. AU, CA, CN, EU, CH, HK, JP, SK, USA
2. AU, CA, CN, EU, CH, HK, JP, SK, USA
3. AU, CA, CN, EU, CH, HK, JP, SK, USA
4. AU, EU, CH, JP, USA
5. AU, USA; Pending: CA, EU, HK, JP

# NUZ-001 Regulatory Strategy for ALS Market Access



# Demonstrating Meaningful Progress

Executed Global License Agreement with Elanco

Regimen "I" commenced in the HEALEY ALS Platform Trial

Successful manufacture of three registration batches of NUZ-001

Promising exploratory top-line results from Phase 1 and OLE study

Australian Patent granted for NUZ-001 – Expiry 2041

Secured registered trademark protection for NEURIZON®

Strengthened preclinical data and understanding of the MOA of NUZ-001

Received ~$6m cash rebate from R&D Tax Incentive for FY2025

R&D Tax Incentive Advance & Overseas Finding Approval

Successfully raised $7.1m through a share placement

Raised $5.88m through Entitlement Offer to Eligible Shareholders

Established a $20m strategic con note facility with Obsidian

# What Comes Next in Our Growth Strategy

## Our Focus Areas:

- Ongoing clinical execution
- Continued data generation
- Progressing the Regulatory Pathway
- Further strengthening of scientific insight
- Partnership expansion and opportunities

## Potential Value Outcomes:

- Clinical de-risking driving higher probability of success
- High-quality data generating long-term value
- Regulatory progress unlocking future milestones and optionality
- Stronger partnerships creating scale and reach
- Sustainable value creation for shareholders


Q&A
Neurizon



# THANK YOU

Registered Address:
Suite 2, Level 11, 385 Bourke Street
Melbourne, VIC 3000 Australia

+61 (3) 9692 7222

enquiries@neurizon.com

Neurizon